AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26240957
Drug: Group singing
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group singing therapy
Trial: 23396206
Drug: Low-dose JX-594
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose JX-594
Trial: 23396206
Drug: High-dose JX-594
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose JX-594
Trial: 21446376
Drug: Intra-arterial lidocaine
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial lidocaine (20 mg)
Trial: 17679043
Drug: ramipril at
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ramipril at 10 mg
Trial: 17679043
Drug: atenolol at
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: atenolol at 100 mg
Trial: 11228370
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated measles vaccine (Hu191)
Trial: 8067495
Drug: 40-60 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40-60 mg/day of fluoxetine
Trial: 8067495
Drug: 20 mg/day
RxNorm normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/day of fluoxetine plus 300-600 mg/day of lithium
Trial: 8067495
Drug: 20 mg/day
RxNorm normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/day of fluoxetine plus 25-50 mg/day of desipramine
Trial: 25180722
Drug: Increasing insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Increasing insulin dose
Trial: 25180722
Drug: Control patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control patients (conventional therapy)
Trial: 23271777
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment for clinically localized prostate cancer
Trial: 17447116
Drug: Alendronate 5
RxNorm normalized name: ALENDRONATE 5MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate 5 mg once daily for 1 year
Trial: 17447116
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no pharmacotherapy)
Trial: 9851950
Drug: Streptokinase (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptokinase (1.5 million units, single intravenous infusion)
Trial: 7989941
Drug: 175 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 175 mg/m2 of Taxol over 24 hours
Trial: 7989941
Drug: 135 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 135 mg/m2 of Taxol over 24 hours
Trial: 7989941
Drug: Taxol administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taxol administered as a 3-hour infusion
Trial: 7989941
Drug: Taxol administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taxol administered as a 24-hour infusion
Trial: 7989941
Drug: 24-hour infusion
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein, recombinant 0.24 MG/ML [Arexvy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-hour infusion
Trial: 2927639
Drug: Lisuride +
RxNorm normalized name: lisuride
DrugBank: Lisuride (DB00589)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisuride + low dose levodopa
Trial: 28007576
Drug: Rifaximin-EIR (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin-EIR (400 mg)
Trial: 26423649
Drug: Ritonavir-boosted protease
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir-boosted protease inhibitor monotherapy (PI-mono)
Trial: 14749158
Drug: Sustained-release bupropion
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sustained-release bupropion (150 mg twice daily)
Trial: 11257560
Drug: RAD 0.035
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAD 0.035 mg/kg (2.5 mg maximum)
Trial: 11257560
Drug: RAD 0.10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAD 0.10 mg/kg (7.5 mg maximum)
Trial: 11257560
Drug: RAD (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAD (both doses)
Trial: 11257560
Drug: RAD (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAD (higher dose)
Trial: 11257560
Drug: RAD co-administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAD co-administration with CsA
Trial: 23719547
Drug: Calcium (600
RxNorm normalized name: calcium carbonate/vitamin D3 250 mg calcium (600 mg)-125 unit ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (600 mg) plus Vitamin D3 (200 IU) supplementation
Trial: 8458113
Drug: fosinopril 10
RxNorm normalized name: fosinopril 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fosinopril 10 mg
Trial: 8458113
Drug: fosinopril 20
RxNorm normalized name: fosinopril 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fosinopril 20 mg
Trial: 8458113
Drug: fosinopril 40
RxNorm normalized name: fosinopril 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fosinopril 40 mg
Trial: 24402825
Drug: Micronized curcumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized curcumin (500 mg)
Trial: 24402825
Drug: Liquid micellar
RxNorm normalized name: Douxo Micellar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid micellar curcumin (500 mg)
Trial: 24402825
Drug: Native curcumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Native curcumin (500 mg)
Trial: 18554243
Drug: Interferon-alpha tailored
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha tailored treatment (5 million units thrice weekly for a median of 10 months, range 6-24 months)
Trial: 18554243
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Interferon-alpha 5 million units thrice weekly for 6 months)
Trial: 11487307
Drug: Pranlukast hydrate
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pranlukast hydrate (225.5 mg), twice a day for 1 week
Trial: 7810780
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment (Group I)
Trial: 2902813
Drug: Ro 15‐1788
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 15‐1788 (0.01 mg/kg) after lormetazepam (0.06 mg/kg)
Trial: 2902813
Drug: Ro 15‐1788
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 15‐1788 (0.01 mg/kg) after flunitrazepam (0.03 mg/kg)
Trial: 2902813
Drug: Ro 15‐1788
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 15‐1788 (0.01 mg/kg) after placebo
Trial: 1392698
Drug: Cyclical estrogen-progestagen
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclical estrogen-progestagen replacement treatment
Trial: 1392698
Drug: Cyclical estrogen-progestagen
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclical estrogen-progestagen replacement treatment plus nandrolone decanoate
Trial: 1392698
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (Cyclical estrogen-progestagen replacement treatment and Cyclical estrogen-progestagen replacement treatment plus nandrolone decanoate)
Trial: 23509019
Drug: Sublingual fentanyl
RxNorm normalized name: fentanyl Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual fentanyl 200 μg
Trial: 23509019
Drug: Sublingual fentanyl
RxNorm normalized name: fentanyl Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual fentanyl 100 μg
Trial: 23509019
Drug: Sublingual fentanyl
RxNorm normalized name: fentanyl Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual fentanyl (both doses)
Trial: 19648781
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of ROL-containing product
Trial: 19648781
Drug: Tryptophan fluorescence
RxNorm normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tryptophan fluorescence spectroscopy in active-agent-treated group
Trial: 15461622
Drug: Bortezomib 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib 1.0 mg/m2
Trial: 20952514
Drug: Bortezomib 1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib 1.3 mg/m2
Trial: 15461622
Drug: Bortezomib alone
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib alone or in combination with dexamethasone
Trial: 11916359
Drug: Captopril 6.25
RxNorm normalized name: captopril 6.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 6.25 mg (n = 85)
Trial: 11916359
Drug: Perindopril 2
RxNorm normalized name: perindopril 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril 2 mg (n = 91)
Trial: 7848395
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg every day
Trial: 7848395
Drug: H2RA (ranitidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2RA (ranitidine 150 mg twice daily or famotidine 20 mg twice daily)
Trial: 2904881
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy with severe hypoglycemic episodes
Trial: 30517065
Drug: 37.5% hydrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 37.5% hydrogen peroxide (HP) gel
Trial: 29961213
Drug: 6% hydrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% hydrogen peroxide (HP) gel
Trial: 23179176
Drug: THC/CBD spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC/CBD spray (2 sprays: 5.4 mg THC and 5.0 mg CBD, 4 sprays: 10.8 mg THC and 10.0 mg CBD, 8 sprays: 21.6 mg THC and 20.0 mg CBD)
Trial: 23179176
Drug: THC/CBD spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC/CBD spray (multiple doses: 2, 4, or 8 sprays once daily for nine consecutive days)
Trial: 21526980
Drug: Tablets containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets containing 400 mg of colostrum protein taken thrice daily with bicarbonate buffer
Trial: 21526980
Drug: Tablets containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets containing 400 mg colostrum protein given with buffer
Trial: 21526980
Drug: Tablets containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets containing 400 mg colostrum protein given without buffer
Trial: 21526980
Drug: Tablets containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets containing 200 mg colostrum protein given without buffer
Trial: 7834164
Drug: Controlled release
RxNorm normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled release dosage form of sodium monofluoro phosphate (NaMFP) at a dose of 160 mg, with a drug to polymer ratio of 1:1.1, delivered over 6 hours.
Trial: 7834164
Drug: Immediate release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release dosage form of sodium monofluoro phosphate (NaMFP) used as a control in a two‐period crossover study.
Trial: 2968885
Drug: Bedtime ultralente
RxNorm normalized name: INSULIN,ULTRALENTE,HUMAN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedtime ultralente administration
Trial: 2968885
Drug: Morning ultralente
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning ultralente administration
Trial: 31149709
Drug: l-leucine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-leucine supplementation (7.5 g·d‐1) with resistance training (3 times/week)
Trial: 31149709
Drug: Placebo (l-alanine)
RxNorm normalized name: L-alanine
DrugBank: Alanine (DB00160)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo (l-alanine) with resistance training (3 times/week)
Trial: 31149709
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (l-leucine and l-alanine)
Trial: 25563714
Drug: Methotrexate (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (10 mg orally once a week for 3 months)
Trial: 25563714
Drug: Placebo (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (treatment as usual)
Trial: 22801943
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily exercise until discharge home and twice weekly as outpatient for 8 weeks
Trial: 20199815
Drug: Intravenous bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus of recombinant human erythropoietin (rhEPO, 50 U/kg)
Trial: 20199815
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group without IV treatment before PCI
Trial: 19246447
Drug: 21‐mg nicotine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21‐mg nicotine patch for 6 months
Trial: 17105759
Drug: PCI and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCI and stenting with optimal medical therapy
Trial: 11759140
Drug: 0.1% study
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% study drug infusion with 0.6 microgram/mL of sufentanil
Trial: 24667461
Drug: GLP-1 and
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 and insulin during normoglycemic-hyperinsulinemic clamp
Trial: 24667461
Drug: GLP-1 and
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 and insulin during normoglycemia
Trial: 17823565
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (oxygen 8 l/min via Venturi face mask)
Trial: 11915588
Drug: 17 beta‐estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17 beta‐estradiol 2 mg plus norethisterone acetate 1 mg (E2 + NETA)
Trial: 9895083
Drug: Diclofenac (IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (IV bolus of 0.7 mg/kg followed by a constant infusion of 0.15 mg x kg(‐1) x h(‐1))
Trial: 9895083
Drug: Saline (equal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (equal volume administered)
Trial: 8273195
Drug: Low-power laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-power laser therapy
Trial: 1830287
Drug: Nifedipine/Mefruside combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine/Mefruside combination
Trial: 6661343
Drug: Timolol treatment
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Timolol treatment for 2 weeks
Trial: 6661343
Drug: Carbimazole treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbimazole treatment after timolol
Trial: 29205909
Drug: HAPA-treatment (sedentary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAPA-treatment (sedentary behavior)
Trial: 28848898
Drug: Indacaterol/glycopyrrolate (IND/GLY)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indacaterol/glycopyrrolate (IND/GLY) 27.5/15.6 or 27.5/31.2 µg twice daily (b.i.d.)
Trial: 28848898
Drug: Indacaterol (IND)
DrugBank: Indacaterol (DB05039)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indacaterol (IND) 75 µg once daily (o.d.)
Trial: 22093775
Drug: Abarelix initiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abarelix initiation therapy for 12 weeks followed by LHRH agonist (leuprolide or goserelin) for 8 weeks
Trial: 22093775
Drug: LHRH agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LHRH agonist therapy (leuprolide or goserelin)
Trial: 22093775
Drug: Abarelix initiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abarelix initiation therapy
Trial: 22093775
Drug: Abarelix initiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abarelix initiation therapy and LHRH agonist maintenance therapy
Trial: 20361916
Drug: Agomelatine 25
RxNorm normalized name: Agomelatine 25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agomelatine 25 mg/d
Trial: 20361916
Drug: Agomelatine 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agomelatine 50 mg/d
Trial: 10404423
Drug: Hoasca (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hoasca (2 ml/kg body weight)
Trial: 19843565
Drug: Supervised exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised exercise therapy for 6 weeks, tailored to individual performance, supervised by a physical therapist, with home exercises for 3 months
Trial: 7916925
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg OKT3 (initial three doses)
Trial: 7916925
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg OKT3 (initial three doses)
Trial: 6778673
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (water, electrolytes, and carbohydrates by intravenous route)
Trial: 26474943
Drug: Telmisartan treated
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telmisartan treated dose arms
Trial: 22306586
Drug: peginterferon alfa-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: peginterferon alfa-2a (40 kD) 180 µg/week and ribavirin 800 mg/day
Trial: 22306586
Drug: threshold exposures
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: threshold exposures to both drugs
Trial: 22306586
Drug: ribavirin 1000
RxNorm normalized name: ribavirin 1000 Dose Pack, 4 Unit Dose Packs, 14 Tablets Each
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ribavirin 1000 or 1200 mg/day
Trial: 11463136
Drug: Perospirone 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perospirone 8 to 48 mg/day
Trial: 11463136
Drug: Haloperidol 2
RxNorm normalized name: haloperidol 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 2 to 12 mg/day
Trial: 11463136
Drug: Mosapramine 50
RxNorm normalized name: mosapramine
DrugBank: Mosapramine (DB13676)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Mosapramine 50 to 300 mg/day
Trial: 2596678
Drug: Interpleural bupivacaine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interpleural bupivacaine, 20 ml of a 0.5% solution with adrenaline 5 micrograms/ml
Trial: 2596678
Drug: Intramuscular pethidine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular pethidine, 1 mg/kg
Trial: 31300528
Drug: Parent-only treatment
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent-only treatment with booster sessions (n = 44)
Trial: 31300528
Drug: Parent-only treatment
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent-only treatment without booster sessions (n = 43)
Trial: 31300528
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (ST) (n = 87)
Trial: 25761977
Drug: Glimepiride ≤6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride ≤6 mg/day
Trial: 23647373
Drug: Tefinostat (CHR‐2845)
RxNorm normalized name: Belinostat
DrugBank: Tefinostat (DB15321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tefinostat (CHR‐2845) at doses of 20‐640 mg, administered orally once daily.
Trial: 17106267
Drug: rDEN2/4Delta30(ME) vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rDEN2/4Delta30(ME) vaccine at a dose of 1,000 PFU
Trial: 17106267
Drug: rDEN2/4Delta30(ME) vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rDEN2/4Delta30(ME) vaccine
Trial: 9280873
Drug: Cisplatin in
RxNorm normalized name: cisplatin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin in combination with prolonged oral etoposide (100 mg/d for 14 days)
Trial: 9280873
Drug: Prolonged oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged oral etoposide therapy (100 mg/d for 14 or 21 days)
Trial: 9280873
Drug: Cisplatin in
RxNorm normalized name: cisplatin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin in combination with prolonged oral etoposide
Trial: 8516090
Drug: Phototherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phototherapy plus oral agar
Trial: 8516090
Drug: Oral agar
RxNorm normalized name: Agar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral agar alone
Trial: 3102414
Drug: 4MV photon
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4MV photon therapy
Trial: 26980264
Drug: Topical diltiazem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diltiazem (3 times a day)
Trial: 24448757
Drug: Cystone supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cystone supplement with cisplatin (group B)